Canada markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2900+0.0400 (+1.23%)
At close: 04:00PM EDT
3.3000 +0.01 (+0.30%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.2500
Open3.1300
Bid3.2700 x 3400
Ask3.5100 x 5300
Day's Range2.9000 - 3.4200
52 Week Range0.7707 - 35.6000
Volume2,531,027
Avg. Volume10,087,818
Market Cap31.587M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-9.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.58
  • GlobeNewswire

    Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in

  • GlobeNewswire

    Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Cla

  • GlobeNewswire

    Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

    Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on July 9, 2024 – – Phase 2a Lomecel-B™ data in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at upcoming Alzheimer’s Ass